The role of methadone in cancer pain treatment - A review

International Journal of Clinical Practice

Volumn 63, Issue 7, 2009, Pages 1095-1109

  Leppert, W ^a,b  

^a Poznan University of Medical Sciences ^*  (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CITALOPRAM; CODEINE; COTRIMOXAZOLE; DESIPRAMINE; DIAZEPAM; DIHYDROCODEINE; DIHYDROERGOTAMINE; FENTANYL; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; FUSIDIC ACID; HYDROMORPHONE; ITRACONAZOLE; KETOCONAZOLE; KETOROLAC; MACROLIDE; METHADONE; MORPHINE; PAROXETINE; QUINOLONE; RIFAMPICIN; RISPERIDONE; SERTRALINE; SPIRONOLACTONE; SULFAMETHOXAZOLE; TRAMADOL; UNINDEXED DRUG; VENLAFAXINE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ANALGESIC ACTIVITY; BIOAVAILABILITY; BONE CANCER; BONE PAIN; CANCER PAIN; CHOREA; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DELIRIUM; DISEASE SEVERITY; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME SUBSTRATE; FECES; GRAPEFRUIT JUICE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERALGESIA; HYPOTENSION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; METABOLITE; MIOSIS; MOUTH ULCER; MUTISM; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUROTOXICITY; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; PLASMA HALF LIFE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; QT PROLONGATION; REPEATED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SEROTONIN SYNDROME; SINGLE DRUG DOSE; TENESMUS; TREATMENT RESPONSE; URINE RETENTION; WITHDRAWAL SYNDROME; XEROSTOMIA; COMPLICATION; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG INTERACTION; NEOPLASM; PAIN;

ANALGESICS, OPIOID; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; METHADONE; NEOPLASMS; PAIN;

EID: 67650730036     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01990.x     Document Type: Review

References (150)

1. World Health Organisation. Cancer Pain Relief and Palliative Care. Geneva : World Health Organisation, 1996.
2. Hanks G, Cherny NI, Fallon M. Opioid analgesic therapy. In : Doyle D, Hanks G, Cherny N, Calman K, eds. Oxford Textbook of Palliative Medicine, 3rd edn. Oxford : Oxford University Press, 2004 : 316 41.
3. Hanks GW, De Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001 84 : 587 93.
4. Mercadante S. Opioid rotation for cancer pain. Rationale and clinical aspects. Cancer 1999 86 : 1856 66.
5. Fishman SM, Wilsey B, Mahajan G, Molina P. Methadone reincarnated: novel clinical applications with related concerns. Pain Med 2002 3 : 339 48.
6. Manfredi PL, Foley KM, Payne R, Houde R, Inturissi CE. Parenteral methadone: an essential medication for the treatment of pain. J Pain Symptom Manage 2003 26 : 687 8.
7. Mercadante S, Casuccio A, Fulfaro F et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001 19 : 2898 904.
8. Mercadante S, Ferrera P, Villari P, Casuccio A. Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol 2005 23 : 5229 34.
9. Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hosp Palliat Med 2005 22 : 291 4.
10. Zimmermann C, Seccareccia D, Booth CM, Cottrell W. Rotation to methadone after opioid dose escalation: how should individualization of dosing occur? J Pain Palliat Care Pharmacother 2005 19 : 25 31. (Pubitemid 41344305)
11. De Stoutz ND, Bruera E, Suazer - Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995 10 : 378 84.
12. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millenium. Drugs 2001 61 : 955 77.
13. Moryl N, Kogan M, Comfort C, Obbens E. Methadone in the treatment of pain and terminal delirium in advanced cancer patients. Palliat Support Care 2005 3 : 311 7.
14. Mancini IL, Hanson J, Neumann CM, Bruera E. Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliat Med 2000 3 : 49 56. (Pubitemid 30262887)
15. Daeninck PJ, Bruera E. Reduction in constipation and laxative requirements following opioid rotation to methadone: a report of four cases. J Pain Symptom Manage 1999 18 : 303 9.
16. Mancini IL, Lossignol DA, Body JJ. Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 2000 12 : 308 13.
17. Scholes CF, Gonty N, Trotman IF. Methadone titration in opioid-resistant cancer pain. Eur J Cancer Care 1999 8 : 26 9.
18. Gannon G. The use of methadone in the care of dying. Eur J Palliat Care 1997 4 : 152 8.
19. Twycross R, Back I. Nausea and vomiting in advanced cancer. Eur J Palliat Care 1998 5 : 39 45.
20. De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996 14 : 2836 42.
21. Bruera E, Palmer JN, Bosnjak S et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004 22 : 185 92.
22. Ventafridda V, Ripamonti C, Bianchi M, Sbanotto A, De Conno F. A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage 1986 1 : 203 7.
23. Twycross R, Wilcock A. Pain relief. In : Twycross R, Wilcock A, eds. Symptom Management in Advanced Cancer, 3rd edn. Oxon : Radcliffe Medical Press, 2001 : 17 68.
24. Shir Y, Shenkman Z, Shavelson V, Davidson EM, Rosen G. Oral methadone for the treatment of severe pain in hospitalized children: a report of five cases. Clin J Pain 1998 14 : 350 3.
25. Davies D, DeVlaming D, Haines C. Methadone analgesia for children with advanced cancer. Pediatr Blood Cancer 2008 51 : 393 7.
26. Mercadante S, Fulfaro F, Dabbene M. Methadone in treatment of tenesmus not responsive to morphine escalation. Support Care Cancer 2001 9 : 129 30.
27. Mannino R, Coyne P, Swainey C, Hansen LA, Lyckholm L. Methadone for cancer-related neuropathic pain: a review of the literature. J Opioid Manag 2006 2 : 269 76.
28. Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001 9 : 73 83. (Pubitemid 32246453)
29. Maneckjee R, Minna JD. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ 1994 5 : 1033 40.
30. Tubaro E, Avico U, Santiangeli C et al. Morphine and methadone impact on human phagocytic physiology. Int J Immunopharmacol 1985 7 : 865 74.
31. Ripamonti C, Bianchi M, Bruera E. Methadone: an orphan drug? J Palliat Med 2004 7 : 73 4.
32. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993 52 : 137 47.
33. Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 1997 223 : 5 8. (Pubitemid 27093006)
34. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995 187 : 165 8.
35. Codd EE, Schank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 1995 274 : 1263 70.
36. Bulka A, Plesan A, Xu X-J, Wiesenfeld-Hallin Z. Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy. Pain 2002 95 : 103 9.
37. Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other μ-opioid receptor agonist analgesics for management of terminal cancer pain. Cancer 1993 72 : 2266 72.
38. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992 49 : 87 91.
39. Mercadante S, Casuccio A, Agnello A, Serretta R, Calderone L, Barresi L. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol 1998 16 : 3656 61.
40. Davies MP. Methadone. In : Davies M, Glare P, Hardy J, eds. Opioids in Cancer Pain. Oxford, New York : Oxford University Press, 2005 : 173 98.
41. Säwe J. High-dose morphine and methadone in cancer patients, clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokin 1986 11 : 87 106. (Pubitemid 16113684)
42. Ferrari A, Coccia CPR, Bertolini A, Sternieri E. Methadone - metabolism, pharmacokinetics and interactions. Pharmacol Res 2004 50 : 551 9.
43. Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 1986 25 : 297 312. (Pubitemid 16085474)
44. Ripamonti C, Zecca A, Bruera E. An update on the clinical use of methadone in cancer pain. Pain 1997 70 : 109 15.
45. Verebely K, Volavka J, Mule S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975 18 : 180 90.
46. Oda Y, Kharasch E. Metabolism of methadone and levo-α- acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearence and bioactivation. J Pharmacol Exp Ther 2001 298 : 1021 32.
47. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004 76 : 250 69.
48. Dean M. Opioids in renal failure and dialysis patient. J Pain Symptom Manage 2004 28 : 497 504. (Pubitemid 39422488)
49. Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematol Oncol Clin North Am 2002 16 : 543 55.
50. Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med 2008 9 : 315 44.
51. Crettol S, Déglon JJ, Besson J et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005 78 : 593 604. (Pubitemid 41773635)
52. Haddad A, Davis M, Lagman R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007 15 : 251 7.
53. Ferrer-Brechner T, Ganz P. Combination therapy with ibuprofen and methadone for chronic cancer pain. Am J Med 1984 77 : 78 83. (Pubitemid 14050202)
54. Mercadante S, Sapio M, Caligara M, Serretta R, Dardanoni G, Barresi L. Opioid-sparing effect of diclofenac in cancer pain. J Pain Symptom Manage 1997 14 : 15 20. (Pubitemid 27287407)
55. Cichewicz DL, Martin ZL, Smith FL, Welch SP. Enhancement of μ opioid antinociception by oral Δ9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 1999 289 : 859 67.
56. Abramson FP. Methadone plasma protein binding: alterations in cancer and displacement from alpha-1-acid glicoprotein. Clin Pharmacol Ther 1982 32 : 652 8.
57. Kostka - Trabka E, Woron J. Izoenzymy cytochromu P450, a problem interakcji lekow. In : Zakowska Z, ed. Interakcje Lekow w Praktyce Kliniczne. Warszawa : Wydawnictwo Lekarskie PZWL, 2006 : 13 24.
58. Wu D, Otton SV, Sproule BA et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993 35 : 30 4.
59. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002 5 : 127 38.
60. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006 32 : 304 15.
61. Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999 17 : 3307 12.
62. Morley JS, Makin MK. The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev 1998 5 : 51 8.
63. Nauck F, Ostgathe C, Dickerson ED. A German model for methadone conversion. Am J Hosp Palliat Care 2001 18 : 200 2.
64. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998 16 : 3216 21.
65. Gagnon B, Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 1999 18 : 120 5.
66. Bruera E, Rico MA, Bertolino M et al. A prospective, open study of oral methadone in the treatment of cancer pain. In : Devor M, Rowbotham MC, Wiesenfeld - Hallin Z, eds. Proceedings of the 9th World Congress of Pain, Progress in Pain Research and Management, Vol. 16. Seattle, WA : IASP Press, 2000 : 957 63.
67. Leppert W. Rola metadonu w leczeniu bolu nowotworowego. Bol 2005 6 : 9 20.
68. Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer pain management. Med J Aust 2000 173 : 536 40.
69. Soares LGL. Methadone for cancer pain: what have we learned from clinical studies? Am J Hosp Palliat Care 2005 22 : 223 7.
70. Mercadante S, Bianchi M, Villari P et al. Opioid plasma concentration during switching from morphine to methadone: preliminary data. Support Care Cancer 2003 11 : 326 31.
71. Mercadante S. Switching to methadone: 'ad libitum' or fixed dose ratio? Palliat Med 2004 18 : 71.
72. Mercadante S, Villari P, Ferrera P, Casuccio A, Gambaro V. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. J Palliat Med 2007 10 : 338 44.
73. Hagen NA, Wasylenko E. Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage 1999 18 : 369 75.
74. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage 2001 22 : 672 87.
75. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996 78 : 852 7.
76. Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain. A retrospective study. Cancer 1998 82 : 1167 83.
77. Ripamonti C, De Conno F, Groff L et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 1998 9 : 79 83. (Pubitemid 28125768)
78. Cornish CJ, Keen JC. An alternative low-dose ad libitum schedule for conversion of other opioids to methadone. Palliat Med 2003 17 : 643 4.
79. Anderson R, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage 2001 21 : 397 406. (Pubitemid 32452140)
80. Gazelle G, Fine PG. Methadone for pain. J Palliat Med 2004 7 : 303 4.
81. Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 2008 9 : 595 612.
82. Laird BJA, Sugden CJ. Methadone titration: still no gauge on the tank. Palliat Med 2005 19 : 568. (Pubitemid 41645518)
83. Hernansanz S, Gutiérrez C, Rubiales ÁS, Flores LA, del Valle ML. Opioid rotation to methadone at home. J Pain Symptom Manage 2006 31 : 2 4. (Pubitemid 43143291)
84. Moryl N, Santiago-Palma J, Kornick C et al. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain 2002 96 : 325 8.
85. Doverty M, Somogyi AA, White JM et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 2001 93 : 155 63.
86. Walker PW, Palla S, Be-Lian P et al. Switching from methadone to a different opioid: what is the equianalgesic dose ratio? J Palliat Med 2008 11 : 1103 8.
87. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005 19 : 13 24.
88. Berdine HJ, Nesbit SA. Equianalgesic dosing of opioids. J Pain Palliat Care Pharmacother 2006 20 : 79 84. (Pubitemid 46018106)
89. Leppert W, Luczak J. The role of methadone in cancer pain treatment - Polish experience. Progr Palliat Care 2005 13 : 269 76.
90. Blackburn D. Methadone: the analgesic. Eur J Palliat Care 2005 12 : 188 91.
91. Fisher K, Stiles C, Hagen NA. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2004 28 : 619 25.
92. Hagen NA, Fisher K, Stiles C. Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study. J Palliat Med 2007 10 : 331 7.
93. Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008 35 : 563 7.
94. Ripamonti C, Zecca E, Brunelli C et al. Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 1995 6 : 841 3.
95. Bruera E, Watanabe S, Fainsinger RL, Spachynski K, Suarez - Almazor M, Inturissi C. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 1995 62 : 141 6.
96. Watanabe S, Belzile M, Kuehn N, Hanson J, Bruera E. Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations. Cancer Treat Rev 1996 22 (Suppl. 1 131 6.
97. Dale O, Sheffels P, Kharasch ED. Bioavailabilities of rectal and oral methadone in healthy subjects. Br J Clin Pharmacol 2004 58 : 156 62.
98. Makin MK, Morley JS. Subcutaneous methadone in terminally ill patients. J Pain Symptom Manage 2000 19 : 237 8.
99. Bruera E, Fainsinger R, Moore M, Thibault R, Spoldi E, Ventafridda V. Local toxicity with subcutaneous methadone. Experience of two centers. Pain 1991 45 : 141 3.
100. Hum A, Fainsinger RL, Bielech M. Subcutaneous methadone - an issue revisited. J Pain Symptom Manage 2007 34 : 573 5.
101. Mathew P, Storey P. Subcutaneous methadone in terminally ill patients: manageable local toxicity. J Pain Symptom Manage 1999 18 : 49 52. (Pubitemid 29344635)
102. Centeno C, Vara F. Intermittent subcutaneous methadone administration in the management of cancer pain. J Pain Palliat Care Pharmacother 2005 19 : 7 12. (Pubitemid 41344303)
103. Guidelines for the Use of Methadone in Cancer Pain. http://www. palliativedrugs.com/methadone.html (accessed November 2008).
104. Vielvoye-Kerkmeer APE, van Mansom I. Re: subcutaneous methadone, an issue revisited. J Pain Symptom Manage 2008 35 : 572.
105. Grochow L, Sheidler V, Grossman S, Green L, Enterline J. Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study. Pain 1989 38 : 151 7.
106. Fitzgibbon DR, Ready B. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain 1997 73 : 259 61.
107. Sabatowski R, Kasper SM, Radbruch L. Patient-controlled analgesia with intravenous L-methadone in a child with cancer pain refractory to high-dose morphine. J Pain Symptom Manage 2002 23 : 3 5. (Pubitemid 34093872)
108. Santiago-Palma J, Khojainova N, Kornick C et al. Intravenous methadone in the management of chronic cancer pain. Safe and effective starting doses when substituting methadone for fentanyl. Cancer 2001 92 : 1919 25.
109. Manfredi PL, Borsook D, Chandler SW, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain 1997 70 : 99 101. (Pubitemid 27128303)
110. Gallagher R. Methadone mouthwash for the management of oral ulcer pain. J Pain Symptom Manage 2004 27 : 390 1.
111. Gallagher RE, Arndt DR, Hunt KL. Analgesic effects of topical methadone: a report of four cases. Clin J Pain 2005 21 : 190 2.
112. Hassenbusch SJ, Portenoy RK, Cousins M et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery - report of an expert panel. J Pain Symptom Manage 2004 27 : 540 63.
113. Shir Y, Rosen G, Zeldin A, Davidson EM. Methadone is safe for treating patients with severe pain. Can J Anesth 2001 48 : 1109 13.
114. Dale O, Hoffer C, Sheffels P, Kharasch ED. Disposition of nasal, intravenous, and oral methadone in healthy volunteers. Clin Pharmacol Ther 2002 72 : 536 45.
115. Weinberg DS, Inturrisi CE, Reidenberg B et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988 44 : 335 42.
116. Nicholson AB Methadone for cancer pain. Cochrane Database Syst Rev 2007, Issue 4. Art. No.: CD003971. DOI : (accessed November 2008).
117. LoVecchio Do F, Pizon A, Riley B, Sami A, D'Incognito C. Onset of symptoms after methadone overdose. Am J Emerg Med 2007 25 : 57 9.
118. Mercadante S, Porzio G, Ferrera P et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 2008 12 : 1040 6.
119. Mercadante S, Casuccio A, Agnello A, Barresi L. Methadone response in advanced cancer patients with pain followed at home. J Pain Symptom Manage 1999 18 : 188 92.
120. Hansen J, Ginman C, Hartvig P et al. Clinical evaluation of oral methadone in treatment of cancer pain. Acta Anaesth Scand 1982 74 (Suppl. 74 124 7.
121. Sarhill N, Davis MP, Walsh D, Nouneh C. Methadone-induced myoclonus in advanced cancer. Am J Hosp Palliat Med 2001 18 : 51 3.
122. Ito S, Liao S. Myoclonus associated with high-dose parenteral methadone. J Palliat Med 2008 11 : 838 41.
123. Lussier D, Cruciani RA. Choreiform movements after a single dose of methadone. J Pain Symptom Manage 2003 26 : 688 91.
124. Bush E, Miller C, Friedman I. A case of serotonin syndrome and mutism associated with methadone. J Palliat Med 2006 9 : 1257 9.
125. Mercadante S, Ferrera P, Villari P, Arcuri E. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 2003 26 : 769 75.
126. Walker PW, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain 2003 103 : 321 4.
127. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose-methadone. Ann Intern Med 2002 137 : 501 4.
128. Kornick CA, Kilborn MJ, Santiago-Palma J et al. QTc interval prolongation associated with intravenous methadone. Pain 2003 105 : 499 506. (Pubitemid 37186911)
129. Cruciani RA, Sekine R, Homel P et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 2005 29 : 385 91.
130. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 2008 121 : 66 71.
131. Manfredi PL, Houde RW. Prescribing methadone, a unique analgesic. J Support Oncol 2003 1 : 216 20.
132. Sekine R, Obbens EAMT, Coyle N, Inturrisi CE. The successful use of parenteral methadone in a patient with a prolonged QTc interval. J Pain Symptom Manage 2007 34 : 566 9.
133. Ower K, Morley-Forster P, Moulin D. Fluctuating QTc interval in an asymptomatic patient treated with methadone for chronic pain. J Opioid Manage 2005 1 : 73 6.
134. Cruciani RA. Methadone: to ECG or not to ECG...that is still the question. J Pain Symptom Manage 2008 36 : 545 52.
135. Oneschuk D, Bruera E. Respiratory depression during methadone rotation in a patient with advanced cancer. J Palliat Care 2000 16 : 50 4.
136. Hunt G, Bruera E. Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom Manage 1995 10 : 401 4.
137. Tarumi Y, Pereira J, Watanabe S. Methadone and fluconazole: respiratory depression by drug interaction. J Pain Symptom Manage 2002 23 : 148 53.
138. Benitez-Rosario MA, Gomez-Ontanon E. Methadone-induced respiratory depression after discontinuing carbamazepine administration. J Pain Symptom Manage 2006 32 : 99 100. (Pubitemid 44108583)
139. Leppert W. The role of methadone in opioid rotation - a Polish experience. Support Care Cancer 2008 Epub ahead of print 29 November 2008; DOI.
140. Mercadante S, Sapio M, Serretta R, Caligara M. Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. Ann Oncol 1996 7 : 613 7.
141. Tse DMW, Sham MMK, Ng DKH, Ma HM. An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliat Med 2003 17 : 206 11.
142. Säwe J, Hansen J, Ginman C et al. Patient-controlled dose regimen of methadone for chronic cancer pain. BMJ 1981 282 : 771 3.
143. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004, Issue 3. Art. No.: CD004847. DOI : (accessed November 2008).
144. Fredheim OMS, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Aanaesth Scand 2008 252 : 879 89.
145. Donnelly S, Davis MP, Walsh D, Naughton M. Morphine in cancer pain management: a practical guide. Support Care Cancer 2002 10 : 13 25.
146. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001 9 : 84 96. (Pubitemid 32246454)
147. Riley J, Eisenberg E, Müller-Schwefe G, Drewers AM, Arendt-Nielsen L. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin 2008 24 : 175 92.
148. Davis MP. Buprenorphine in cancer pain. Support Care Cancer 2005 13 : 878 87.
149. Mercadante S, Ferrera P, Villari P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer 2007 15 : 441 4.
150. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manag 1997 13 : 254 61.